Loading company
Scinai Immunotherapeutics Ltd.
SCNI · Nasdaq · ·
$1.39-6.1%Sep 29 close
- 1M
- -44.6%
- 6M
- -75.0%
- 1Y
- -89.0%
- 5Y
- -99.9%
SCNI · Nasdaq · ·
$1.39-6.1%Sep 29 close
The quarter ending June 30, 2024, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2024 | 3 months toMar 31, 2023 | Change |
|---|---|---|---|
| Profit | -$6.6M | -$3.5M | -88.90% |
| Profit per share | -$0.00 | $400.00 | -100.00% |
| Free Cash Flow | -$2.2M | -$10.5M | +78.55% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Scinai Immunotherapeutics Ltd. has no earnings call transcript available.
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies and the operation of a contract development and manufacturing organization. The Company is advancing therapeutic programs based on technology licensed from the Max Planck Society and pursuant to its option arrangement with PinCell S.r.l. Scinai also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Scinai Immunotherapeutics Ltd. filed on August 26, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.